what's your favorite of these sword-related actions/plot devices... 🎤
gifting someone a sword (especially as significant gesture e.g. betrothal gift)
drawing someone else's sword from the scabbard suddenly and without permission
using someone else's sword as a way to remember them after they've passed
you're not worthy of me drawing my sword/it's almost always left in the scabbard
sword with some measure of sentience e.g. ability to jostle/laugh/purr
emotionally significant "may I please borrow your sword" moment
plot-significant sword name change
Remaining time: 4 days 13 hours
there are of course one william possibilities and im sure ive left some good ones off... feel free to tell me abt some other good ones and their associated stories 👀
tried the gochujang butter noodles recipe and both the hubs and I thought it was a little too sweet. will probably skip the honey next time. (now that we're both diabetic, probably a good idea anyway hah.) also it seemed to lack a savory element -- perhaps some chorizo next time? and some cheese.
all i want for 2026 is that gigantic rancid AI bubble to finally burst in such a catastrophic way that the consequences will be so good and i'll never have to see another AI generated image ever again
Eridians cant "hold their breath" like humans do, their vents dont close completly so water can still get in, if they fall in water they drown and die. safe to say rocky is not a fan of when grace does it for fun xD
(i got the inspo for this from this fic: Enrichment by alatarmaia4, please check it out it is so funny)
the new york times has such a great series of elevated butter noodles, if you ever want a super fast easy dinner that still feels grown up and you can emulsify pasta water + butter together basically the sky is your limit
ya got
gochujang butter noodles
peanut butter noodles
chili crisp fettuccine alfredo
miso butter noodles
any one of these + a bag of salad or whatever vegetable side you find easiest/cheapest, and you've got yourself a full meal that tastes far above the effort you put in.
For millions of people managing type 2 diabetes, mornings begin the same way — a needle, a dose, and a quiet mental note to do it all again
"For millions of people managing type 2 diabetes, mornings begin the same way — a needle, a dose, and a quiet mental note to do it all again tomorrow.
That routine just changed.
On March 26, 2026, the U.S. Food and Drug Administration approved Awiqli (insulin icodec-abae), developed by Novo Nordisk, as the first and only once-weekly basal insulin ever approved for adults with type 2 diabetes in the United States.
This is not a minor update to an existing drug.
It is the first entirely new class of basal insulin to reach U.S. patients in more than two decades.
Instead of injecting insulin every single day, people with type 2 diabetes using Awiqli will only need one shot per week, on the same day, every week.
That means reducing from 365 injections a year down to just 52.
For anyone who has ever felt the weight of that daily ritual — the anxiety of forgetting, the physical discomfort, the constant reminder that their body needs help — this approval represents something much bigger than a dosing schedule.
It represents relief.
How the Drug Actually Works
Understanding why this injection lasts a full week requires a quick look inside the body.
Most traditional basal insulins are absorbed into the bloodstream and begin breaking down within 24 hours, which is why patients need a fresh dose every day to maintain stable blood sugar levels.
Awiqli works differently.
Its active ingredient, insulin icodec-abae, is engineered to loosely attach to a blood protein called albumin, which is found naturally and abundantly in the bloodstream.
This attachment creates a slow-release reservoir.
Instead of flooding the system and fading fast, the insulin releases gradually and consistently over an entire seven-day period, keeping blood sugar in a healthy range around the clock...
The FDA reviewed and ultimately declined to approve it for people with type 1 diabetes, citing concerns about a modestly increased risk of hypoglycemia in that population specifically.
Some regulatory agencies in other countries, including the European Union, Canada, Australia, and Japan, have approved Awiqli for both type 1 and type 2 diabetes, but for now the U.S. approval is limited to type 2...
What Comes Next
Awiqli is not standing alone in this space for long.
Eli Lilly is developing its own once-weekly basal insulin, called efsitora alfa, which is currently in late-stage clinical trials.
If that drug also earns FDA approval, it would give patients and doctors two once-weekly options to choose from, allowing for personalized decisions based on a patient’s health profile, insurance coverage, and individual response.
The broader direction of travel in diabetes care is unmistakable.
Fewer injections, smarter formulations, and better integration with digital tools like continuous glucose monitors and insulin-tracking apps are all converging toward a future where managing diabetes requires less daily mental effort without becoming any less medically precise...
A Small Shot With Large Implications
It is easy to look at a once-weekly injection and see only a scheduling change.
But the science behind Awiqli, the scale of the ONWARDS trials, and the consistent satisfaction reported by patients all point toward something that matters far more than convenience.
Diabetes management has always asked a lot of people.
It asks for daily vigilance, daily discipline, and a daily willingness to confront one’s own condition, sometimes in uncomfortable or inconvenient circumstances.
Anything that reduces that load, without reducing the quality of care, is worth taking seriously.
For the more than 37 million Americans living with diabetes, and the hundreds of millions more around the world, a simpler weekly routine could mean the difference between a treatment plan that works on paper and one that actually works in a person’s life.
That is the real significance of what the FDA approved on March 26, 2026.
Not just a new drug.
A new way of keeping people healthy, one week at a time."
Navigating gender dysphoria? Be heard and be counted in the science.
Join our confidential, cross-country study of 18-25 year olds to tell your story, challenge preconceptions, and have YOUR experience reflected in the science on queer youth | ayagdos.org
IF YOU SEE THIS DO NOT TAKE THIS SURVEY. THIS IS A BAD FAITH STUDY TARGETING TRANS YOUNG PEOPLE FROM SOME OF THE LEADING MINDS OF THE ANTI TRANS MOVEMENT. DO NOT TAKE AT ALL.
Alright now that it’s not the middle of the night let me add some more context: All leading researchers of this study—J. Michael Bailey of Northwestern University, Lisa Littman, and Kenneth Zucker—have longstanding professional associations with research frameworks that challenge or reject gender-affirming models of care. Many trans-led organizations, advocates, and researchers are urging families NOT to participate in this study, as the data collected will be skewed to promote false and harmful narratives about trans people, and will be weaponized by lawmakers looking to pass discriminatory bills.
(Information above from PFLAG National)
Bailey has spent the last 20+ years of his professional career attacking the Trans community — he has been accused of misconduct MULTIPLE times around not getting informed consent for the research he does.
PLEASE SPREAD THE WORD THEY ARE BLAZING THEIR POST TRYING TO REACH THE QUEER COMMUNITY ON TUMBLR.
I see your “Rocky swears like a sailor but only in pitches humans can’t hear/refuses to teach Grace what those words mean” and raise you “Rocky swears like a sailor and now has to explain to Grace that ‘bad bad bad’ isn’t actually a sequence you play on your Eridian speech piano in polite company.”
Grace is both horrified and amused to realise that a more accurate translation for what Rocky’s been saying is “shit shit shit”.
I like how the window-washing guy plays along. You get a feeling that this is a regular encounter…
(And of course the outside of the window is nice and clean, but the inside has a constellation of little paw-prints…)
